- Home
- CINGW vs HLN Comparison
CINGW vs HLN Comparison
Compare CINGW & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINGW
- HLN
- Stock Information
- Founded
- CINGW N/A
- HLN 2022
- Country
- CINGW United States
- HLN United Kingdom
- Employees
- CINGW 13
- HLN N/A
- Industry
- CINGW Biotechnology: Pharmaceutical Preparations
- HLN Package Goods/Cosmetics
- Sector
- CINGW Health Care
- HLN Consumer Discretionary
- Exchange
- CINGW Nasdaq
- HLN Nasdaq
- Market Cap
- CINGW N/A
- HLN 45.6B
- IPO Year
- CINGW 2021
- HLN N/A
- Fundamental
- Price
- CINGW $0.03
- HLN $10.19
- Analyst Decision
- CINGW
- HLN Buy
- Analyst Count
- CINGW 0
- HLN 1
- Target Price
- CINGW N/A
- HLN $10.95
- AVG Volume (30 Days)
- CINGW N/A
- HLN 15.0M
- Earning Date
- CINGW N/A
- HLN 02-27-2025
- Dividend Yield
- CINGW N/A
- HLN 1.65%
- EPS Growth
- CINGW N/A
- HLN 38.94
- EPS
- CINGW N/A
- HLN 0.20
- Revenue
- CINGW N/A
- HLN $14,062,871,660.00
- Revenue This Year
- CINGW N/A
- HLN $4.78
- Revenue Next Year
- CINGW N/A
- HLN $4.75
- P/E Ratio
- CINGW N/A
- HLN $25.12
- Revenue Growth
- CINGW N/A
- HLN N/A
- 52 Week Low
- CINGW N/A
- HLN $8.12
- 52 Week High
- CINGW N/A
- HLN $10.80
- Technical
- Relative Strength Index (RSI)
- CINGW N/A
- HLN 52.01
- Support Level
- CINGW N/A
- HLN $10.14
- Resistance Level
- CINGW N/A
- HLN $10.34
- Average True Range (ATR)
- CINGW 0.00
- HLN 0.23
- MACD
- CINGW 0.00
- HLN 0.04
- Stochastic Oscillator
- CINGW 0.00
- HLN 75.28
About CINGW Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.